Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7412 USD | +0.84% | -8.15% | +30.04% |
05-23 | Oppenheimer Adjusts Price Target on Viracta Therapeutics to $11 From $13, Maintains Outperform Rating | MT |
05-14 | Viracta Therapeutics Appoints Michael Faerm CFO | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.04% | 28.87M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- VIRX Stock
- News Viracta Therapeutics, Inc.
- Viracta Therapeutics Appoints Michael Faerm CFO